Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments

Molecular Genetics and Metabolism

Volumn 92, Issue 1-2, 2007, Pages 23-35

  Babady, Ngolela E ^a,b   Carelle, Nadege ^c   Wells, Robert D ^d   Rouault, Tracey A ^e   Hirano, Michio ^f   Lynch, David R ^g   Delatycki, Martin B ^h   Wilson, Robert B ⁱ   Isaya, Grazia ^a,b   Puccio, Hélène ^c  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug therapy; Frataxin; Friedreich's Ataxia; Iron metabolism; Mitochondria

Indexed keywords

1,4 BENZOQUINONE; ABC TRANSPORTER; ABC TRANSPORTER B7; BETA GALACTOSIDASE; DEFERIPRONE; DEFEROXAMINE; DNA; FERROCHELATASE; FRATAXIN; IDEBENONE; IRON; MESYLIC ACID DERIVATIVE; MITOQUINONE MESYLATE; PEPTIDE; PIOGLITAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; RECOMBINANT ERYTHROPOIETIN; TRANSACTIVATOR OF TRANSCRIPTION PEPTIDE; UNCLASSIFIED DRUG; VIRUS VECTOR;

BIOTECHNOLOGY; CLINICAL TRIAL; DNA DAMAGE; DNA DETERMINATION; DRUG EFFICACY; FRIEDREICH ATAXIA; FRIEDREICH ATAXIA GENE; GASTROINTESTINAL SYMPTOM; GENE; GENETIC ANALYSIS; HEALTH CARE ORGANIZATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IRON DEPLETION; IRON METABOLISM; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; STRUCTURE ANALYSIS;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; FRIEDREICH ATAXIA; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); TRINUCLEOTIDE REPEATS; UNITED STATES;

EID: 34548388956     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2007.05.009     Document Type: Review

References (82)

1. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F., Canizares J., Koutnikova H., Bidichandani S.I., Gellera C., Brice A., Trouillas P., De Michele G., Filla A., De Frutos R., Palau F., Patel P.I., Di Donato S., Mandel J.L., Cocozza S., Koenig M., and Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
2. Burnett R., Melander C., Puckett J.W., Son L.S., Wells R.D., Dervan P.B., and Gottesfeld J.M. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc. Natl. Acad. Sci. USA 103 (2006) 11497-11502
3. Napierala M., Dere R., Vetcher A., and Wells R.D. Structure-dependent recombination hot spot activity of GAA.TTC sequences from intron 1 of the Friedreich's ataxia gene. J. Biol. Chem. 279 (2004) 6444-6454
4. Son L.S., Bacolla A., and Wells R.D. Sticky DNA: in vivo formation in E. coli and in vitro association of long GAA*TTC tracts to generate two independent supercoiled domains. J. Mol. Biol. 360 (2006) 267-284
5. Saveliev A., Everett C., Sharpe T., Webster Z., and Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422 (2003) 909-913
6. Hiragami K., and Festenstein R. Heterochromatin protein 1: a pervasive controlling influence. Cell Mol. Life Sci. 62 (2005) 2711-2726
7. Herman D., Jenssen K., Burnett R., Soragni E., Perlman S.L., and Gottesfeld J.M. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2 (2006) 551-558
8. Gomez-Sebastian S., Gimenez-Cassina A., Diaz-Nido J., Lim F., and Wade-Martins R. Infectious Delivery and Expression of a 135 kb Human FRDA Genomic DNA Locus Complements Friedreich's Ataxia Deficiency in Human Cells. Mol. Ther. 15 (2007) 248-254
9. Schoenfeld R.A., Napoli E., Wong A., Zhan S., Reutenauer L., Morin D., Buckpitt A.R., Taroni F., Lonnerdal B., Ristow M., Puccio H., and Cortopassi G.A. Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. Hum. Mol. Genet. 14 (2005) 3787-3799
10. Stehling O., Elsasser H.P., Bruckel B., Muhlenhoff U., and Lill R. Iron-sulfur protein maturation in human cells: evidence for a function of frataxin. Hum. Mol. Genet. 13 (2004) 3007-3015
11. Ramazzotti A., Vanmansart V., and Foury F. Mitochondrial functional interactions between frataxin and Isu1p, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae. FEBS Lett. 557 (2004) 215-220
12. Yoon T., and Cowan J.A. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 125 (2003) 6078-6084
13. Yoon T., and Cowan J.A. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem. 279 (2004) 25943-25946
14. Zhang Y., Lyver E.R., Knight S.A., Lesuisse E., and Dancis A. Frataxin and mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for heme synthesis. J. Biol. Chem. 280 (2005) 19794-19807
15. Muhlenhoff U., Richhardt N., Gerber J., and Lill R. Characterization of iron-sulfur protein assembly in isolated mitochondria. A requirement for ATP, NADH, and reduced iron. J. Biol. Chem. 277 (2002) 29810-29816
16. Muhlenhoff U., Gerber J., Richhardt N., and Lill R. Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. Embo J. 22 (2003) 4815-4825
17. Lesuisse E., Santos R., Matzanke B.F., Knight S.A., Camadro J.M., and Dancis A. Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum. Mol. Genet. 12 (2003) 879-889
18. Park S., Gakh O., O'Neill H.A., Mangravita A., Nichol H., Ferreira G.C., and Isaya G. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J. Biol. Chem. 278 (2003) 31340-31351
19. Foury F., and Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 411 (1997) 373-377
20. Babcock M., de Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., Pandolfo M., and Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276 (1997) 1709-1712
21. Gakh O., Adamec J., Gacy A.M., Twesten R.D., Owen W.G., and Isaya G. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry 41 (2002) 6798-6804
22. O'Neill H.A., Gakh O., Park S., Cui J., Mooney S.M., Sampson M., Ferreira G.C., and Isaya G. Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry 44 (2005) 537-545
23. Gakh O., Park S., Liu G., Macomber L., Imlay J.A., Ferreira G.C., and Isaya G. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum. Mol. Genet. 15 (2006) 467-479
24. Karlberg T., Schagerlof U., Gakh O., Park S., Ryde U., Lindahl M., Leath K., Garman E., Isaya G., and Al-Karadaghi S. The structures of frataxin oligomers reveal the mechanism for the delivery and detoxification of iron. Structure 14 (2006) 1535-1546
25. Adamec J., Rusnak F., Owen W.G., Naylor S., Benson L.M., Gacy A.M., and Isaya G. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. 67 (2000) 549-562
26. Chantrel-Groussard K., Geromel V., Puccio H., Koenig M., Munnich A., Rotig A., and Rustin P. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet. 10 (2001) 2061-2067
27. Karthikeyan G., Santos J.H., Graziewicz M.A., Copeland W.C., Isaya G., Van Houten B., and Resnick M.A. Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum. Mol. Genet. 12 (2003) 3331-3342
28. Karthikeyan G., Lewis L.K., and Resnick M.A. The mitochondrial protein frataxin prevents nuclear damage. Hum. Mol. Genet. 11 (2002) 1351-1362
29. Gerber J., Muhlenhoff U., and Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 4 (2003) 906-911
30. O'Neill H.A., Gakh O., and Isaya G. Supramolecular assemblies of human frataxin are formed via subunit-subunit interactions mediated by a non-conserved amino-terminal region. J. Mol. Biol. 345 (2005) 433-439
31. Napoli E., Taroni F., and Cortopassi G.A. Frataxin, iron-sulfur clusters, heme, ROS, and aging. Antioxid Redox Signal 8 (2006) 506-516
32. He Y., Alam S.L., Proteasa S.V., Zhang Y., Lesuisse E., Dancis A., and Stemmler T.L. Yeast frataxin solution structure, iron binding, and ferrochelatase interaction. Biochemistry 43 (2004) 16254-16262
33. Nair M., Adinolfi S., Pastore C., Kelly G., Temussi P., and Pastore A. Solution structure of the bacterial frataxin ortholog, CyaY: mapping the iron binding sites. Structure 12 (2004) 2037-2048
34. Aloria K., Schilke B., Andrew A., and Craig E.A. Iron-induced oligomerization of yeast frataxin homologue Yfh1 is dispensable in vivo. EMBO Rep. 5 (2004) 1096-1101
35. Cook J.D., Bencze K.Z., Jankovic A.D., Crater A.K., Busch C.N., Bradley P.B., Stemmler A.J., Spaller M.R., and Stemmler T.L. Monomeric yeast frataxin is an iron-binding protein. Biochemistry 45 (2006) 7767-7777
36. Sazanov L.A., and Hinchliffe P. Structure of the hydrophilic domain of respiratory complex I from Thermus thermophilus. Science 311 (2006) 1430-1436
37. Ristow M., Pfister M.F., Yee A.J., Schubert M., Michael L., Zhang C.Y., Ueki K., Michael II M.D., Lowell B.B., and Kahn C.R. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc. Natl. Acad. Sci. USA 97 (2000) 12239-12243
38. Gonzalez-Cabo P., Vazquez-Manrique R.P., Garcia-Gimeno M.A., Sanz P., and Palau F. Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum. Mol. Genet. 14 (2005) 2091-2098
39. Vazquez-Manrique R.P., Gonzalez-Cabo P., Ros S., Aziz H., Baylis H.A., and Palau F. Reduction of Caenorhabditis elegans frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutant. Faseb J. 20 (2006) 172-174
40. Yoon T., Dizin E., and Cowan J.A. N-terminal iron-mediated self-cleavage of human frataxin: regulation of iron binding and complex formation with target proteins. J. Biol. Inorg. Chem. 12 (2007) 535-542
41. Cavadini P., Adamec J., Taroni F., Gakh O., and Isaya G. Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates. J. Biol. Chem. 275 (2000) 41469-41475
42. Cavadini P., O'Neill H.A., Benada O., and Isaya G. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum. Mol. Genet. 11 (2002) 217-227
43. Dhe-Paganon S., Shigeta R., Chi Y.I., Ristow M., and Shoelson S.E. Crystal structure of human frataxin. J. Biol. Chem. 275 (2000) 30753-30756
44. Babady N.E., Pang Y.P., Elpeleg O., and Isaya G. Cryptic proteolytic activity of dihydrolipoamide dehydrogenase. Proc. Natl. Acad. Sci. USA 104 (2007) 6158-6163
45. Odievre M.H., Chretien D., Munnich A., Robinson B.H., Dumoulin R., Masmoudi S., Kadhom N., Rotig A., Rustin P., and Bonnefont J.P. A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit gene (DLD) resulting in an atypical form of alpha-ketoglutarate dehydrogenase deficiency. Hum. Mutat. 25 (2005) 323-324
46. Shany E., Saada A., Landau D., Shaag A., Hershkovitz E., and Elpeleg O.N. Lipoamide dehydrogenase deficiency due to a novel mutation in the interface domain. Biochem. Biophys. Res. Commun. 262 (1999) 163-166
47. Condo I., Ventura N., Malisan F., Rufini A., Tomassini B., and Testi R. In vivo maturation of human frataxin. Hum. Mol. Genet. (2007)
48. Gordon D.M., Shi Q., Dancis A., and Pain D. Maturation of frataxin within mammalian and yeast mitochondria: one-step processing by matrix processing peptidase. Hum. Mol. Genet. 8 (1999) 2255-2262
49. Koutnikova H., Campuzano V., and Koenig M. Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum. Mol. Genet. 7 (1998) 1485-1489
50. Condo I., Ventura N., Malisan F., Tomassini B., and Testi R. A pool of extramitochondrial frataxin that promotes cell survival. J. Biol. Chem. 281 (2006) 16750-16756
51. Li J., Kogan M., Knight S.A., Pain D., and Dancis A. Yeast mitochondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins, cellular iron uptake, and iron distribution. J. Biol. Chem. 274 (1999) 33025-33034
52. Rouault T.A., and Tong W.H. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat. Rev. Mol. Cell Biol. 6 (2005) 345-351
53. Tong W.H., and Rouault T.A. Functions of mitochondrial ISCU and cytosolic ISCU in mammalian iron-sulfur cluster biogenesis and iron homeostasis. Cell Metab. 3 (2006) 199-210
54. Tong W.H., and Rouault T.A. Metabolic regulation of citrate and iron by aconitases: role of iron-sulfur cluster biogenesis. Biometals 20 (2007) 549-564
55. Michael S., Petrocine S.V., Qian J., Lamarche J.B., Knutson M.D., Garrick M.D., and Koeppen A.H. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 5 (2006) 257-267
56. Zhang Y., Lyver E.R., Knight S.A., Pain D., Lesuisse E., and Dancis A. Mrs3p, Mrs4p, and frataxin provide iron for Fe-S cluster synthesis in mitochondria. J. Biol. Chem. 281 (2006) 22493-22502
57. Al-Karadaghi S., Franco R., Hansson M., Shelnutt J.A., Isaya G., and Ferreira G.C. Chelatases: distort to select?. Trends Biochem. Sci. 31 (2006) 135-142
58. Cavadini P., Biasiotto G., Poli M., Levi S., Verardi R., Zanella I., Derosas M., Ingrassia R., Corrado M., and Arosio P. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 109 (2007) 3552-3559
59. Shan Y., Napoli E., and Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the Nfs1/ISCU complex and multiple mitochondrial chaperones. Hum. Mol. Genet. 16 (2007) 929-941
60. Lu C., and Cortopassi G. Frataxin knockdown causes loss of cytoplasmic iron-sulfur cluster functions, redox alterations and induction of heme transcripts. Arch. Biochem. Biophys. 457 (2007) 111-122
61. Miranda C.J., Santos M.M., Ohshima K., Smith J., Li L., Bunting M., Cossee M., Koenig M., Sequeiros J., Kaplan J., and Pandolfo M. Frataxin knockin mouse. FEBS Lett. 512 (2002) 291-297
62. Coppola G., Choi S.H., Santos M.M., Miranda C.J., Tentler D., Wexler E.M., Pandolfo M., and Geschwind D.H. Gene expression profiling in frataxin deficient mice: microarray evidence for significant expression changes without detectable neurodegeneration. Neurobiol. Dis. 22 (2006) 302-311
63. Irazusta V., Cabiscol E., Reverter-Branchat G., Ros J., and Tamarit J. Manganese is the link between frataxin and iron-sulfur deficiency in the yeast model of Friedreich ataxia. J. Biol. Chem. 281 (2006) 12227-12232
64. Ventura N., Rea S., Henderson S.T., Condo I., Johnson T.E., and Testi R. Reduced expression of frataxin extends the lifespan of Caenorhabditis elegans. Aging Cell 4 (2005) 109-112
65. Llorens J.V., Navarro J.A., Martinez-Sebastian M.J., Baylies M.K., Schneuwly S., Botella J.A., and Molto M.D. Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. Faseb J. 21 (2007) 333-344
66. Anderson P.R., Kirby K., Hilliker A.J., and Phillips J.P. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum. Mol. Genet. 14 (2005) 3397-3405
67. Bulteau A.L., O'Neill H.A., Kennedy M.C., Ikeda-Saito M., Isaya G., and Szweda L.I. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305 (2004) 242-245
68. Al-Mahdawi S., Pinto R.M., Ruddle P., Carroll C., Webster Z., and Pook M. GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 84 (2004) 301-310
69. Al-Mahdawi S., Pinto R.M., Varshney D., Lawrence L., Lowrie M.B., Hughes S., Webster Z., Blake J., Cooper J.M., King R., and Pook M.A. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88 (2006) 580-590
70. Sarsero J.P., Li L., Holloway T.P., Voullaire L., Gazeas S., Fowler K.J., Kirby D.M., Thorburn D.R., Galle A., Cheema S., Koenig M., Williamson R., and Ioannou P.A. Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic mice. Mamm Genome 15 (2004) 370-382
71. Gimenez-Cassina A., Lim F., and Diaz-Nido J. Differentiation of a human neuroblastoma into neuron-like cells increases their susceptibility to transduction by herpesviral vectors. J. Neurosci. Res. 84 (2006) 755-767
72. Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schurmann B., Zimmer A., and Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25 (2005) 7805-7812
73. Sarsero J.P., Li L., Wardan H., Sitte K., Williamson R., and Ioannou P.A. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med. 5 (2003) 72-81
74. Chaires J.B. Competition dialysis: an assay to measure the structural selectivity of drug-nucleic acid interactions. Curr. Med. Chem. Anticancer Agents 5 (2005) 339-352
75. Grant L., Sun J., Xu H., Subramony S.H., Chaires J.B., and Hebert M.D. Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich's ataxia. FEBS Lett. 580 (2006) 5399-5405
76. Sturm B., Stupphann D., Kaun C., Boesch S., Schranzhofer M., Wojta J., Goldenberg H., and Scheiber-Mojdehkar B. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur. J. Clin. Invest. 35 (2005) 711-717
77. Puccio H., Simon D., Cossee M., Criqui-Filipe P., Tiziano F., Melki J., Hindelang C., Matyas R., Rustin P., and Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet 27 (2001) 181-186
78. Whitnall M., and Richardson D.R. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol. 13 (2006) 186-197
79. Boddaert N., Le Quan Sang K.H., Rotig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J.C., Munnich A., and Cabantchik Z.I. Selective iron chelation in Friedreich ataxia. Biological and clinical implications. Blood (2007)
80. Angdisen J., Moore V.D., Cline J.M., Payne R.M., and Ibdah J.A. Mitochondrial trifunctional protein defects: molecular basis and novel therapeutic approaches. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5 (2005) 27-40
81. Del Gaizo V., and Payne R.M. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther. 7 (2003) 720-730
82. Del Gaizo V., MacKenzie J.A., and Payne R.M. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 80 (2003) 170-180